{"query":"investor page abivax soci\u00e9t\u00e9 anonyme","results":[{"t":"Investor Relations | Abivax","u":"https:\/\/ir.abivax.com\/","d":"ir.abivax.com","p":"The Investor Relations website contains information about Abivax's business for stockholders, potential investors, and financial analysts."},{"t":"Press Releases","u":"https:\/\/ir.abivax.com\/news-and-events\/news-releases","d":"ir.abivax.com","p":"Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone \u00b7 Abivax Provides Operational and Key Program Update \u00b7 Abivax releases the results of its\u00a0..."},{"t":"ABIVAX (ABVX) Investor Relations Material","u":"https:\/\/quartr.com\/companies\/abivax-soci-t-anonyme_17462","d":"quartr.com","p":"Access ABIVAX Soci\u00e9t\u00e9 Anonyme (ABVX) Investor Relations material, such as Live Earnings Calls, Transcripts, Slides, Reports, and Estimates using Quartr."},{"t":"Financial Reports","u":"https:\/\/ir.abivax.com\/financial-information\/financial-reports","d":"ir.abivax.com","p":"Investor Contact. Patrick Malloy Head of Investor Relations. Email investors@abivax.com. Phone +1 847 987 4878. Subscribe to our Email Alerts. Subscribe."},{"t":"ABIVAX Soci\u00e9t\u00e9 Anonyme (ABVX) Company Profile & Facts","u":"https:\/\/finance.yahoo.com\/quote\/ABVX\/profile\/","d":"finance.yahoo.com","p":"See the company profile for ABIVAX Soci\u00e9t\u00e9 Anonyme (ABVX) including business summary, industry\/sector information, number of employees, business summary,\u00a0..."},{"t":"ABIVAX Soci\u00e9t\u00e9 Anonyme (ABVX) - Total Ownership and ...","u":"https:\/\/finchat.io\/company\/ENXTPA-ABVX\/ownership\/","d":"finchat.io","p":"Deep Track Capital, LP is the largest shareholder of ABIVAX Soci\u00e9t\u00e9 Anonyme with 2.51% of the shares. View the entire shareholder list and ownership changes\u00a0..."},{"t":"About Abivax SA (ABVX)","u":"https:\/\/www.investing.com\/equities\/abivax-sa-company-profile","d":"investing.com","p":"This page offers an in-depth profile of Abivax SA, including a general overview of the company's business and key management."},{"t":"Abivax releases the results of its May 30, 2024 Ordinary and ...","u":"https:\/\/abivax.gcs-web.com\/news-releases\/news-release-details\/abivax-releases-results-its-may-30-2024-ordinary-and","d":"abivax.gcs-web.com","p":"May 30, 2024 \u2014 Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the\u00a0..."},{"t":"Abivax | Official Website","u":"https:\/\/www.abivax.com\/?lang=fr","d":"abivax.com","p":"Abivax is a clinical-stage biotechnology company driven to advance human health by regulating the immune response through the power of microRNA."},{"t":"Is ABIVAX Soci\u00e9t\u00e9 Anonyme (EPA:ABVX) A Risky ...","u":"https:\/\/simplywall.st\/stocks\/fr\/pharmaceuticals-biotech\/epa-abvx\/abivax-societe-anonyme-shares\/news\/is-abivax-socit-anonyme-epaabvx-a-risky-investment","d":"simplywall.st","p":"Apr 24, 2024 \u2014 Simply put, the fact that ABIVAX Soci\u00e9t\u00e9 Anonyme has more cash than debt is arguably a good indication that it can manage its debt safely."}]}